Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.
Kurs
Kursziel
72,69 €

72,69 €

-0,29 %
-0,21
-0,29 %
-

-

 
15:37 / Tradegate WKN: A3D3G6 / Name: Ge Healthcare Technologies Inc / Aktie / ? /
Finanztrends

Ge Healthcare Technologies Inc Aktie

Ein geringer Kursrückgang bei Ge Healthcare Technologies Inc heute, um -0,29 %.

Was spricht für und gegen Ge Healthcare Technologies Inc in den nächsten Jahren?

Pro
?
M************
?
W******* i* V********
?
L*********** I********** f** d** n******* J****
Kontra
?
A****************
?
M****
?
U****************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen

News

GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers: https://mms.businesswire.com/media/20230105005172/en/1673594/5/GE_HealthCare_Logo_%28Jan_2023%29.jpg
GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers


GE HealthCare (Nasdaq: GEHC) announced today that it has named Roland Rott president and CEO of Imaging and Phil Rackliffe president and CEO of Ultrasound and IGT. Both leaders bring to their roles

GE HealthCare Increases Access to Precision Care Tools, Encouraging the Continued Adoption and Practice of More Personalized Medicine Around the World: https://mms.businesswire.com/media/20230105005172/en/1673594/5/GE_HealthCare_Logo_%28Jan_2023%29.jpg
GE HealthCare Increases Access to Precision Care Tools, Encouraging the Continued Adoption and Practice of More Personalized Medicine Around the World


GE HealthCare once again joins the world’s top medical and academic institutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting to discuss today’s healthcare

GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five...: https://mms.businesswire.com/media/20230105005172/en/1673594/5/GE_HealthCare_Logo_%28Jan_2023%29.jpg
GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five...


 



GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and